DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

New Legislation Impacting Your Profession
June 29, 2021

Click here to view a full list of bill summaries from the 2021 Florida Legislative Session that may impact your profession. Continue reading


Third Quarter Performance Report
June 9, 2021

Released for the
2020-21 Fiscal Year Continue reading